Economic aspects of pharmacovigilance in the pharmaceutical industry
Abadie, E.; Souetre, E.
Therapie 48(2): 125-127
1993
ISSN/ISBN: 0040-5957 PMID: 8351680 Document Number: 409270
The economical aspects of pharmacovigilance in the pharmaceutical industry can be assessed by two ways. First the balance between cost of avoiding adverse drug reactions (ADR) and cost of ADR should be evaluated during the development. The company will have to take into account both efficacy and safety of its compound. However if it increases the costs of avoiding ADR it will reduce the costs of avoiding ADR occurring after commercialization. On the other hand the cost of side effects of a marketed compound can also be appreciated. This assessment will always have to be comparative with an other drug and to take into account the benefit of both drugs, if their efficacy is not deemed identical.